However, the FDA has not approved it for human use
A clear demonstration was obtained that BPC 157 stimulated both the egr-1 gene (critical in proliferation, differentiation, and inflammation during cholestatic liver injury, cytokine and growth factor generation, and early extracellular matrix (collagen) formation) (Kim et al., 2006
The way it works with the compounding pharmacy is, because those are brand-named drugs, and they are not patented for the peptide, they're patented for the delivery system, which is the pen, which most people don't realize
Tirzepatide receptor pharmacology and predicted receptor occupancy GIPR-forward dual-incretin design, cAMP-biased GLP-1R with low beta-arrestin, GCGR negative control (EC50 329 nM)